25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BCLI (Brainstorm Cell Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Brainstorm Cell Therapeutics Inc together

I guess you are interested in Brainstorm Cell Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Brainstorm Cell Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Brainstorm Cell Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Brainstorm Cell Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Brainstorm Cell Therapeutics Inc

I send you an email if I find something interesting about Brainstorm Cell Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Brainstorm Cell Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Brainstorm Cell Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.58
Expected worth in 1 year
$-0.83
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
$-0.24
Return On Investment
-34.8%

For what price can you sell your share?

Current Price per Share
$0.70
Expected price per share
$0.521 - $1
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Brainstorm Cell Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$0.70
Intrinsic Value Per Share
$-13.28 - $-11.37
Total Value Per Share
$-13.86 - $-11.95

2.2. Growth of Brainstorm Cell Therapeutics Inc (5 min.)




Is Brainstorm Cell Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$6m-$3.8m-$2.9m-43.1%

How much money is Brainstorm Cell Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m-$2.3m-$472.6k-16.5%
Net Profit Margin-87.5%-562.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Brainstorm Cell Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#779 / 849

Most Revenue
#559 / 849

Most Profit
#345 / 849

Most Efficient
#437 / 849
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Brainstorm Cell Therapeutics Inc?

Welcome investor! Brainstorm Cell Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Brainstorm Cell Therapeutics Inc.

First you should know what it really means to hold a share of Brainstorm Cell Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Brainstorm Cell Therapeutics Inc is $0.7. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Brainstorm Cell Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Brainstorm Cell Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.58. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Brainstorm Cell Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-40.0%-0.28-39.4%-0.23-32.9%-0.36-51.2%-0.48-68.1%-0.40-56.7%
Usd Book Value Change Per Share0.1319.3%-0.06-8.7%0.011.6%-0.12-17.4%-0.08-11.5%-0.06-8.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.1319.3%-0.06-8.7%0.011.6%-0.12-17.4%-0.08-11.5%-0.06-8.4%
Usd Price Per Share1.12-1.22-0.37-1.58-3.15-3.55-
Price to Earnings Ratio-1.00--1.09--0.40--0.98--1.61--1.84-
Price-to-Total Gains Ratio8.30-9.04-0.45-2.74-3.57--1.07-
Price to Book Ratio-1.92--1.78--0.95-0.44-1.31-5.74-
Price-to-Total Gains Ratio8.30-9.04-0.45-2.74-3.57--1.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.7
Number of shares1428
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.06-0.08
Usd Total Gains Per Share-0.06-0.08
Gains per Quarter (1428 shares)-87.05-115.02
Gains per Year (1428 shares)-348.19-460.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-348-3580-460-470
20-696-7060-920-930
30-1045-10540-1380-1390
40-1393-14020-1840-1850
50-1741-17500-2300-2310
60-2089-20980-2760-2770
70-2437-24460-3220-3230
80-2786-27940-3681-3690
90-3134-31420-4141-4150
100-3482-34900-4601-4610

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.011.00.00.0%0.019.00.00.0%1.038.00.02.6%5.087.00.05.4%
Book Value Change Per Share2.02.00.050.0%5.06.00.045.5%8.011.00.042.1%12.027.00.030.8%28.064.00.030.4%
Dividend per Share0.00.04.00.0%0.00.011.00.0%0.00.019.00.0%0.00.039.00.0%0.00.092.00.0%
Total Gains per Share2.02.00.050.0%5.06.00.045.5%8.011.00.042.1%12.027.00.030.8%28.064.00.030.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Brainstorm Cell Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.135-0.061+145%0.011+1083%-0.122+190%-0.081+160%-0.059+144%
Book Value Per Share---0.584-0.659+13%-0.375-36%-0.432-26%0.736-179%0.676-186%
Current Ratio--0.1780.121+46%0.308-42%0.276-36%1.773-90%3.288-95%
Debt To Asset Ratio--3.3603.919-14%1.911+76%2.450+37%1.560+115%1.066+215%
Debt To Equity Ratio----0%-0%0.777-100%0.689-100%1.467-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--3822242.0804033131.188-5%-3086012.980+181%8458877.327-55%35317126.450-89%39884443.687-90%
Eps---0.280-0.276-1%-0.230-18%-0.358+28%-0.477+70%-0.397+42%
Ev To Ebitda Ratio---0.379-0.337-11%0.208-282%-0.404+7%-1.571+315%-2.146+466%
Free Cash Flow Per Share---0.338-0.228-32%-0.359+6%-0.358+6%-0.468+39%-0.370+10%
Free Cash Flow To Equity Per Share---0.077-0.063-18%0.091-185%-0.097+26%-0.076-2%-0.038-51%
Gross Profit Margin--1.0001.0000%1.304-23%1.083-8%1.048-5%1.023-2%
Intrinsic Value_10Y_max---11.368----------
Intrinsic Value_10Y_min---13.275----------
Intrinsic Value_1Y_max---1.393----------
Intrinsic Value_1Y_min---1.464----------
Intrinsic Value_3Y_max---3.992----------
Intrinsic Value_3Y_min---4.309----------
Intrinsic Value_5Y_max---6.358----------
Intrinsic Value_5Y_min---7.034----------
Market Cap7263276.300-60%11621242.08012659631.188-8%3815987.020+205%16416513.690-29%32711284.345-64%36784264.200-68%
Net Profit Margin----0.8750%-5.6260%-5.3880%-10.2580%-7.6570%
Operating Margin----0.9390%-5.1280%-5.3260%-10.3210%-7.6940%
Operating Ratio---0.939-100%5.248-100%5.321-100%10.391-100%7.677-100%
Pb Ratio-1.199+38%-1.919-1.775-7%-0.952-50%0.442-534%1.312-246%5.742-133%
Pe Ratio-0.625+38%-1.001-1.086+8%-0.400-60%-0.978-2%-1.606+60%-1.840+84%
Price Per Share0.700-60%1.1201.220-8%0.368+205%1.582-29%3.153-64%3.545-68%
Price To Free Cash Flow Ratio-0.519+38%-0.830-2.158+160%-0.360-57%-1.448+75%-1.753+111%-4.817+481%
Price To Total Gains Ratio5.188-60%8.3019.036-8%0.453+1732%2.736+203%3.570+133%-1.073+113%
Quick Ratio--0.1090.081+35%0.280-61%0.303-64%1.954-94%5.056-98%
Return On Assets---1.131-1.223+8%-0.560-51%-0.841-26%-0.571-50%-0.431-62%
Return On Equity----0%-0%-0.4490%-0.4020%-0.7290%
Total Gains Per Share--0.135-0.061+145%0.011+1083%-0.122+190%-0.081+160%-0.059+144%
Usd Book Value---6057000.000-6833750.000+13%-3886333.333-36%-4485727.273-26%7635684.211-179%7014153.846-186%
Usd Book Value Change Per Share--0.135-0.061+145%0.011+1083%-0.122+190%-0.081+160%-0.059+144%
Usd Book Value Per Share---0.584-0.659+13%-0.375-36%-0.432-26%0.736-179%0.676-186%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--3822242.0804033131.188-5%-3086012.980+181%8458877.327-55%35317126.450-89%39884443.687-90%
Usd Eps---0.280-0.276-1%-0.230-18%-0.358+28%-0.477+70%-0.397+42%
Usd Free Cash Flow---3502000.000-2370000.000-32%-3724333.333+6%-3719636.364+6%-4851789.474+39%-3840102.564+10%
Usd Free Cash Flow Per Share---0.338-0.228-32%-0.359+6%-0.358+6%-0.468+39%-0.370+10%
Usd Free Cash Flow To Equity Per Share---0.077-0.063-18%0.091-185%-0.097+26%-0.076-2%-0.038-51%
Usd Market Cap7263276.300-60%11621242.08012659631.188-8%3815987.020+205%16416513.690-29%32711284.345-64%36784264.200-68%
Usd Price Per Share0.700-60%1.1201.220-8%0.368+205%1.582-29%3.153-64%3.545-68%
Usd Profit---2903000.000-2862000.000-1%-2389333.333-18%-3716363.636+28%-4949526.316+70%-4119769.231+42%
Usd Revenue---212250.000-100%236000.000-100%153454.545-100%148421.053-100%154769.231-100%
Usd Total Gains Per Share--0.135-0.061+145%0.011+1083%-0.122+190%-0.081+160%-0.059+144%
 EOD+1 -7MRQTTM+14 -18YOY+17 -163Y+19 -155Y+16 -1810Y+16 -18

3.3 Fundamental Score

Let's check the fundamental score of Brainstorm Cell Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.625
Price to Book Ratio (EOD)Between0-1-1.199
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.109
Current Ratio (MRQ)Greater than10.178
Debt to Asset Ratio (MRQ)Less than13.360
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.131
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Brainstorm Cell Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.046
Ma 20Greater thanMa 500.699
Ma 50Greater thanMa 1000.685
Ma 100Greater thanMa 2000.872
OpenGreater thanClose0.675
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2025-10-16 19:18:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Brainstorm Cell Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Brainstorm Cell Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-87.5%+87.5%
TTM-87.5%YOY-562.6%+475.0%
TTM-87.5%5Y-1,025.8%+938.3%
5Y-1,025.8%10Y-765.7%-260.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--76.0%+76.0%
TTM-87.5%-167.3%+79.8%
YOY-562.6%-186.4%-376.2%
3Y-538.8%-263.9%-274.9%
5Y-1,025.8%-345.5%-680.3%
10Y-765.7%-477.5%-288.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Brainstorm Cell Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Brainstorm Cell Therapeutics Inc to theΒ Biotechnology industry mean.
  • -113.1% Return on Assets means thatΒ Brainstorm Cell Therapeutics Inc generatedΒ $-1.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is -113.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -122.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-113.1%TTM-122.3%+9.2%
TTM-122.3%YOY-56.0%-66.4%
TTM-122.3%5Y-57.1%-65.2%
5Y-57.1%10Y-43.1%-14.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-113.1%-12.0%-101.1%
TTM-122.3%-11.9%-110.4%
YOY-56.0%-11.0%-45.0%
3Y-84.1%-12.0%-72.1%
5Y-57.1%-11.7%-45.4%
10Y-43.1%-13.8%-29.3%
4.3.1.3. Return on Equity

Shows how efficient Brainstorm Cell Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Brainstorm Cell Therapeutics Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Brainstorm Cell Therapeutics Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-40.2%+40.2%
5Y-40.2%10Y-72.9%+32.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--14.8%+14.8%
YOY--15.0%+15.0%
3Y-44.9%-16.6%-28.3%
5Y-40.2%-16.9%-23.3%
10Y-72.9%-19.5%-53.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Brainstorm Cell Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Brainstorm Cell Therapeutics Inc is operatingΒ .

  • Measures how much profit Brainstorm Cell Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Brainstorm Cell Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-93.9%+93.9%
TTM-93.9%YOY-512.8%+418.9%
TTM-93.9%5Y-1,032.1%+938.2%
5Y-1,032.1%10Y-769.4%-262.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--153.1%+153.1%
TTM-93.9%-265.6%+171.7%
YOY-512.8%-246.9%-265.9%
3Y-532.6%-247.4%-285.2%
5Y-1,032.1%-338.0%-694.1%
10Y-769.4%-498.1%-271.3%
4.3.2.2. Operating Ratio

Measures how efficient Brainstorm Cell Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.939-0.939
TTM0.939YOY5.248-4.309
TTM0.9395Y10.391-9.452
5Y10.39110Y7.677+2.714
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.868-1.868
TTM0.9392.773-1.834
YOY5.2482.820+2.428
3Y5.3213.575+1.746
5Y10.3914.664+5.727
10Y7.6776.406+1.271
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Brainstorm Cell Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Brainstorm Cell Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.18Β means the company has $0.18 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 0.178. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.121. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.178TTM0.121+0.056
TTM0.121YOY0.308-0.187
TTM0.1215Y1.773-1.652
5Y1.77310Y3.288-1.514
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1783.414-3.236
TTM0.1213.605-3.484
YOY0.3084.036-3.728
3Y0.2764.431-4.155
5Y1.7735.716-3.943
10Y3.2886.128-2.840
4.4.3.2. Quick Ratio

Measures if Brainstorm Cell Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Brainstorm Cell Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.11Β means the company can pay off $0.11 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 0.109. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.081. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.109TTM0.081+0.028
TTM0.081YOY0.280-0.199
TTM0.0815Y1.954-1.873
5Y1.95410Y5.056-3.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1092.911-2.802
TTM0.0813.135-3.054
YOY0.2803.825-3.545
3Y0.3034.359-4.056
5Y1.9545.692-3.738
10Y5.0566.524-1.468
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Brainstorm Cell Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Brainstorm Cell Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Brainstorm Cell Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 3.36Β means that Brainstorm Cell Therapeutics Inc assets areΒ financed with 336.0% credit (debt) and the remaining percentage (100% - 336.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 3.360. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 3.919. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.360TTM3.919-0.559
TTM3.919YOY1.911+2.009
TTM3.9195Y1.560+2.359
5Y1.56010Y1.066+0.495
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3600.342+3.018
TTM3.9190.360+3.559
YOY1.9110.331+1.580
3Y2.4500.344+2.106
5Y1.5600.348+1.212
10Y1.0660.378+0.688
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Brainstorm Cell Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Brainstorm Cell Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.689-0.689
5Y0.68910Y1.467-0.778
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.399-0.399
TTM-0.439-0.439
YOY-0.429-0.429
3Y0.7770.471+0.306
5Y0.6890.471+0.218
10Y1.4670.518+0.949
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Brainstorm Cell Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Brainstorm Cell Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -1.00 means the investor is paying $-1.00Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The EOD is -0.625. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.001. Based on the earnings, the company is expensive. -2
  • The TTM is -1.086. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.625MRQ-1.001+0.375
MRQ-1.001TTM-1.086+0.085
TTM-1.086YOY-0.400-0.686
TTM-1.0865Y-1.606+0.520
5Y-1.60610Y-1.840+0.234
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.625-2.877+2.252
MRQ-1.001-2.296+1.295
TTM-1.086-2.701+1.615
YOY-0.400-3.622+3.222
3Y-0.978-3.843+2.865
5Y-1.606-6.007+4.401
10Y-1.840-6.984+5.144
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The EOD is -0.519. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.830. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.158. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.519MRQ-0.830+0.311
MRQ-0.830TTM-2.158+1.329
TTM-2.158YOY-0.360-1.798
TTM-2.1585Y-1.753-0.405
5Y-1.75310Y-4.817+3.064
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.519-3.674+3.155
MRQ-0.830-2.920+2.090
TTM-2.158-3.869+1.711
YOY-0.360-4.296+3.936
3Y-1.448-5.305+3.857
5Y-1.753-8.442+6.689
10Y-4.817-9.887+5.070
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Brainstorm Cell Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -1.92 means the investor is paying $-1.92Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Brainstorm Cell Therapeutics Inc:

  • The EOD is -1.199. Based on the equity, the company is expensive. -2
  • The MRQ is -1.919. Based on the equity, the company is expensive. -2
  • The TTM is -1.775. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.199MRQ-1.919+0.719
MRQ-1.919TTM-1.775-0.144
TTM-1.775YOY-0.952-0.823
TTM-1.7755Y1.312-3.087
5Y1.31210Y5.742-4.430
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.1992.524-3.723
MRQ-1.9192.062-3.981
TTM-1.7752.248-4.023
YOY-0.9522.465-3.417
3Y0.4422.704-2.262
5Y1.3123.834-2.522
10Y5.7424.581+1.161
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Brainstorm Cell Therapeutics Inc.

4.8.1. Institutions holding Brainstorm Cell Therapeutics Inc

Institutions are holding 3.789% of the shares of Brainstorm Cell Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30CALDWELL SUTTER CAPITAL INC1.5132015700900
2025-06-30Geode Capital Management, LLC0.526054582-3583-6.1601
2025-06-30Vanguard Group Inc0.267202772400
2025-06-30Gunderson Capital Management Inc0.25010.012225950259500
2025-06-30BlackRock Inc0.242602517200
2025-06-30Liberty Wealth Management, LLC0.21840.0042266600
2025-06-30Weaver Consulting Group0.15060.00481562300
2025-06-30UBS Group AG0.1193012380121274793.2806
2025-06-30Traynor Capital Management, Inc0.1060.000911000110000
2025-06-30LPL Financial Corp0.1031010698106980
2025-06-30Almanack Investment Partners, LLC.0.09640.001810000100000
2025-06-30Morgan Stanley - Brokerage Accounts0.055905803146533.7713
2025-06-30HARBOUR INVESTMENTS, INC.0.03430.0001355935590
2025-06-30Advisor Group Holdings, Inc.0.017201785663.8394
2025-06-30Wells Fargo & Co0.01290133800
2025-06-30Citigroup Inc0.006406636630
2025-06-30Activest Wealth Management0.00320.000133400
2025-06-30Bangor Savings Bank0.0026026600
2025-06-30SBI Securities Co Ltd0.00210218-2-0.9091
2025-06-30JONES FINANCIAL COMPANIES LLLP0.0021021600
Total 3.72960.0239386986+71943+18.6%

4.9.2. Funds holding Brainstorm Cell Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Northern Trust Extended Eq Market Idx0.05130.0001532000
2025-06-30NT Ext Equity Mkt Idx Fd - L0.05130.0001532000
2025-06-30Extended Equity Market Fund K0.039104057-81-1.9575
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.01930200300
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.01501555-4-0.2566
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.01450.0001150122317.4491
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.01220.0001126812680
2025-06-30BNYM Mellon SL Market Completion UC10.00560.0001583-2-0.3419
2025-06-30Extended Equity Market Fund M0.00490511-7-1.3514
2025-06-30Northern Trust Wilshire 50000.0015015500
2025-06-30BNYM Mellon NSL Mkt Completion Fund Inst0.00040.0001431030.303
Total 0.21510.000622316+1407+6.3%

5.3. Insider Transactions

Insiders are holding 11.924% of the shares of Brainstorm Cell Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-09-30Chaim LebovitsBUY14663.45
2024-07-19Ibrahim B. DagherSELL42005.25
2023-09-01Stacy LindborgBUY76626.55
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Total Other Income Expense Net 441-101340-1242169225-555-330



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets2,566
Total Liabilities8,623
Total Stockholder Equity-6,057
 As reported
Total Liabilities 8,623
Total Stockholder Equity+ -6,057
Total Assets = 2,566

Assets

Total Assets2,566
Total Current Assets1,515
Long-term Assets1,051
Total Current Assets
Cash And Cash Equivalents 824
Net Receivables 106
Other Current Assets 585
Total Current Assets  (as reported)1,515
Total Current Assets  (calculated)1,515
+/-0
Long-term Assets
Property Plant Equipment 826
Long-term Assets Other 225
Long-term Assets  (as reported)1,051
Long-term Assets  (calculated)1,051
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,528
Long-term Liabilities95
Total Stockholder Equity-6,057
Total Current Liabilities
Short-term Debt 482
Short Long Term Debt 101
Accounts payable 5,997
Other Current Liabilities 2,049
Total Current Liabilities  (as reported)8,528
Total Current Liabilities  (calculated)8,629
+/- 101
Long-term Liabilities
Long-term Liabilities  (as reported)95
Long-term Liabilities  (calculated)0
+/- 95
Total Stockholder Equity
Common Stock16
Retained Earnings -232,403
Other Stockholders Equity 226,330
Total Stockholder Equity (as reported)-6,057
Total Stockholder Equity (calculated)-6,057
+/-0
Other
Capital Stock16
Cash and Short Term Investments 824
Common Stock Shares Outstanding 8,620
Liabilities and Stockholders Equity 2,566
Net Debt -247
Net Invested Capital -5,956
Net Working Capital -7,013
Property Plant and Equipment Gross 826
Short Long Term Debt Total 577



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-30
> Total Assets 
89
85
57
45
39
40
39
16
68
55
308
879
870
828
589
860
978
725
722
695
678
986
1,083
1,084
1,123
1,052
875
841
825
805
757
1,992
1,475
1,383
1,089
4,403
3,617
3,245
2,744
2,249
1,850
5,721
5,138
4,752
3,794
6,212
4,726
4,193
12,524
11,400
9,911
22,387
20,363
18,359
17,080
13,814
13,154
11,722
10,766
9,032
8,001
11,335
11,423
9,413
21,020
13,769
11,228
11,851
8,864
7,811
6,534
18,071
19,221
32,691
51,259
48,571
42,235
34,538
29,277
25,791
18,961
13,254
8,451
7,872
5,747
5,682
4,208
3,348
5,683
2,025
1,832
3,571
2,566
2,5663,5711,8322,0255,6833,3484,2085,6825,7477,8728,45113,25418,96125,79129,27734,53842,23548,57151,25932,69119,22118,0716,5347,8118,86411,85111,22813,76921,0209,41311,42311,3358,0019,03210,76611,72213,15413,81417,08018,35920,36322,3879,91111,40012,5244,1934,7266,2123,7944,7525,1385,7211,8502,2492,7443,2453,6174,4031,0891,3831,4751,9927578058258418751,0521,1231,0841,08398667869572272597886058982887087930855681639403945578589
   > Total Current Assets 
35
35
16
10
10
7
5
5
68
55
306
645
452
378
144
365
383
147
134
98
123
350
258
104
165
148
59
77
89
95
87
1,373
927
869
579
3,885
3,134
2,797
2,304
1,775
1,401
5,285
4,874
4,300
3,290
5,672
4,446
3,853
12,207
11,107
9,578
22,078
20,061
18,091
16,788
13,510
12,813
11,385
10,444
8,725
7,682
10,951
9,623
7,865
19,563
12,621
10,270
8,257
5,535
4,672
3,360
15,205
16,628
30,337
43,242
41,030
35,187
27,944
23,280
19,260
12,806
7,502
3,106
2,929
1,213
1,539
1,899
1,259
3,816
364
385
2,332
1,515
1,5152,3323853643,8161,2591,8991,5391,2132,9293,1067,50212,80619,26023,28027,94435,18741,03043,24230,33716,62815,2053,3604,6725,5358,25710,27012,62119,5637,8659,62310,9517,6828,72510,44411,38512,81313,51016,78818,09120,06122,0789,57811,10712,2073,8534,4465,6723,2904,3004,8745,2851,4011,7752,3042,7973,1343,8855798699271,37387958977591481651042583501239813414738336514437845264530655685571010163535
       Cash And Cash Equivalents 
35
22
15
10
10
6
5
5
68
55
275
527
306
301
87
290
290
53
60
30
4
241
86
86
57
21
2
2
2
2
1
1,215
725
750
93
3,664
2,899
2,390
1,923
1,145
843
4,783
1,317
1,868
755
329
3,503
3,027
11,328
8,969
4,251
3,494
1,301
710
428
2,213
944
955
547
604
5,784
2,464
2,483
3,246
2,262
697
942
3,238
1,126
2,095
536
12,471
12,153
24,770
37,829
35,933
30,565
25,695
18,856
15,151
9,005
4,144
772
2,021
546
1,222
1,300
779
3,469
168
187
1,644
824
8241,6441871683,4697791,3001,2225462,0217724,1449,00515,15118,85625,69530,56535,93337,82924,77012,15312,4715362,0951,1263,2389426972,2623,2462,4832,4645,7846045479559442,2134287101,3013,4944,2518,96911,3283,0273,5033297551,8681,3174,7838431,1451,9232,3902,8993,664937507251,215122222157868624143060532902908730130652727555685561010152235
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,769
1,772
1,780
4,786
0
0
0
1,600
4,290
17,855
18,394
16,441
15,527
10,733
10,537
10,238
9,443
7,743
933
8,083
5,273
2,359
15,177
10,194
6,122
2,987
1,575
34
33
2,020
4,040
4,038
4,107
4,114
4,047
2,114
3,238
3,246
3,239
3,249
2,211
206
202
196
0
0
0
0
0
0
0
00000001962022062,2113,2493,2393,2463,2382,1144,0474,1144,1074,0384,0402,02033341,5752,9876,12210,19415,1772,3595,2738,0839337,7439,44310,23810,53710,73315,52716,44118,39417,8554,2901,6000004,7861,7801,7722,769000000000000000000000000000000000000000000
       Net Receivables 
0
13
13
0
0
13
0
0
0
0
32
88
116
47
28
45
63
63
42
35
87
75
137
66
68
87
12
43
52
93
86
158
177
119
427
221
186
369
312
482
421
449
742
617
620
502
910
792
831
450
1,005
693
252
823
759
484
1,265
110
306
202
735
318
672
1,117
964
492
2,009
795
1,917
1,924
2,375
435
259
1,473
304
255
183
85
86
61
117
58
91
44
93
66
0
26
33
40
63
67
106
1066763403326066934491581176186851832553041,4732594352,3751,9241,9177952,0094929641,1176723187352023061101,2654847598232526931,005450831792910502620617742449421482312369186221427119177158869352431287686613775873542636345284711688320000130013130
       Other Current Assets 
1
1
1
0
0
0
0
0
0
0
0
31
30
30
29
29
30
31
32
32
32
34
0
38
40
40
0
32
35
0
86
158
25
119
59
221
49
38
69
148
137
53
47
43
135
55
33
34
48
88
32
36
114
117
74
80
67
82
148
176
230
86
1,103
1,143
1,160
1,238
1,103
1,237
917
619
432
279
176
56
984
656
328
50
1,086
785
362
51
91
658
372
55
548
454
314
156
135
621
585
5856211351563144545485537265891513627851,08650328656984561762794326199171,2371,1031,2381,1601,1431,1038623017614882678074117114363288483433551354347531371486938492215911925158860353204040380343232323130292930303100000000111
   > Long-term Assets 
54
50
42
35
30
34
34
16
0
11
2
234
419
450
445
495
596
579
588
598
555
636
0
980
958
904
0
764
736
710
670
619
548
514
510
518
483
448
440
474
449
436
264
452
504
540
280
340
317
293
333
309
302
268
292
304
341
337
322
307
319
384
1,800
1,548
1,457
1,148
958
3,594
3,329
3,139
3,174
2,866
2,593
2,354
8,017
7,541
7,048
6,594
5,997
6,531
6,155
5,752
5,345
4,943
4,534
4,143
2,309
2,089
1,867
1,661
1,447
1,239
1,051
1,0511,2391,4471,6611,8672,0892,3094,1434,5344,9435,3455,7526,1556,5315,9976,5947,0487,5418,0172,3542,5932,8663,1743,1393,3293,5949581,1481,4571,5481,8003843193073223373413042922683023093332933173402805405044522644364494744404484835185105145486196707107367640904958980063655559858857959649544545041923421101634343035425054
       Property Plant Equipment 
0
0
0
35
30
24
18
0
0
0
2
228
408
433
421
411
489
480
491
504
482
549
739
866
821
783
743
704
664
624
575
538
492
452
419
418
380
341
314
328
298
273
247
234
263
267
258
327
302
272
313
290
282
268
271
281
318
312
297
281
295
358
392
412
596
564
651
3,562
3,298
3,107
3,142
2,835
2,567
2,327
7,991
7,514
6,940
6,562
5,970
6,504
6,128
5,729
5,322
4,920
4,512
4,122
2,102
1,887
1,668
1,458
1,241
1,035
826
8261,0351,2411,4581,6681,8872,1024,1224,5124,9205,3225,7296,1286,5045,9706,5626,9407,5147,9912,3272,5672,8353,1423,1073,2983,562651564596412392358295281297312318281271268282290313272302327258267263234247273298328314341380418419452492538575624664704743783821866739549482504491480489411421433408228200018243035000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
107
126
146
151
163
189
218
241
273
22
13
15
0
20
19
20
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000002019200151322273241218189163151146126107103000000000000000000000000000000000000
       Intangible Assets 
54
50
42
0
0
0
0
11
0
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
00000300000000000000000000000000000000000000000000000000000000000000000000000000000110110000425054
       Other Assets 
0
0
0
0
0
0
0
-5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
81
56
62
91
100
103
107
126
146
151
163
189
218
241
273
22
0
0
0
20
19
20
0
0
23
23
25
25
26
24
26
1,408
1,136
861
584
307
0
31
32
32
31
26
27
26
27
108
32
27
27
27
23
23
23
0
0
0
0
0
0
0
0
0
00000000023232327272732108272627263132323103075848611,1361,4082624262525232300201920000222732412181891631511461261071031009162568100000000000000000000000-50000000
> Total Liabilities 
46
50
28
25
27
35
38
48
5
17
108
175
439
603
752
8,770
1,702
2,147
2,538
3,186
3,702
3,129
3,511
3,528
2,716
2,839
2,951
3,122
3,117
3,373
2,500
1,989
1,945
2,006
1,548
1,737
1,370
909
1,256
1,432
1,597
1,262
1,156
1,271
1,439
1,677
1,987
3,333
1,924
2,499
3,236
2,726
2,526
2,838
2,952
1,242
1,282
1,195
864
789
711
6,140
5,543
5,579
8,147
3,791
6,212
11,525
13,380
14,588
18,757
9,060
9,399
6,713
15,795
12,370
12,063
9,612
9,935
11,304
11,110
11,866
11,466
12,712
9,629
8,264
9,066
8,898
9,210
8,082
9,596
11,028
8,623
8,62311,0289,5968,0829,2108,8989,0668,2649,62912,71211,46611,86611,11011,3049,9359,61212,06312,37015,7956,7139,3999,06018,75714,58813,38011,5256,2123,7918,1475,5795,5436,1407117898641,1951,2821,2422,9522,8382,5262,7263,2362,4991,9243,3331,9871,6771,4391,2711,1561,2621,5971,4321,2569091,3701,7371,5482,0061,9451,9892,5003,3733,1173,1222,9512,8392,7163,5283,5113,1293,7023,1862,5382,1471,7028,7707526034391751081754838352725285046
   > Total Current Liabilities 
5
18
7
25
27
35
38
48
5
17
108
169
428
586
729
1,067
1,677
2,112
2,497
3,135
3,648
2,679
3,228
3,428
2,579
2,703
2,859
3,041
3,024
3,272
2,388
1,872
1,863
1,909
1,423
1,610
1,276
808
1,135
1,290
1,450
1,098
1,139
1,061
1,200
1,386
1,332
1,607
1,782
2,395
3,113
2,726
2,526
2,838
2,952
1,242
1,282
1,195
864
789
711
6,140
5,543
5,579
8,147
3,791
6,212
8,480
10,543
11,958
17,654
8,252
8,840
6,429
11,233
8,191
8,059
5,846
6,317
7,372
7,846
8,948
8,800
10,422
7,691
6,321
7,800
6,831
7,691
7,082
8,978
10,901
8,528
8,52810,9018,9787,0827,6916,8317,8006,3217,69110,4228,8008,9487,8467,3726,3175,8468,0598,19111,2336,4298,8408,25217,65411,95810,5438,4806,2123,7918,1475,5795,5436,1407117898641,1951,2821,2422,9522,8382,5262,7263,1132,3951,7821,6071,3321,3861,2001,0611,1391,0981,4501,2901,1358081,2761,6101,4231,9091,8631,8722,3883,2723,0243,0412,8592,7032,5793,4283,2282,6793,6483,1352,4972,1121,6771,06772958642816910817548383527257185
       Short-term Debt 
0
0
0
21
21
31
31
31
0
31
0
0
0
0
0
496
959
1,144
1,126
1,530
1,856
1,154
1,341
1,385
436
461
0
412
206
264
370
9
1
41
137
137
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,263
2,416
2,448
2,432
5,310
4,598
4,074
3,470
1,461
1,629
1,478
1,460
1,427
1,389
1,354
2,612
0
1,176
1,132
1,140
849
1,643
482
4821,6438491,1401,1321,17602,6121,3541,3891,4271,4601,4781,6291,4613,4704,0744,5985,3102,4322,4482,4161,2630000000000000000000000000000000000137137411937026420641204614361,3851,3411,1541,8561,5301,1261,144959496000003103131312121000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,200
101
1011,2000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
1
8
1
0
1
1
0
0
0
5
108
169
428
586
729
571
718
969
0
1,605
1,792
1,525
0
812
709
737
0
764
809
777
600
539
566
446
307
401
681
253
385
451
660
267
551
405
594
676
455
573
1,027
1,579
1,766
1,155
1,021
530
1,452
567
630
619
712
699
227
275
2,101
3,935
4,182
2,602
4,548
5,029
8,765
9,144
14,677
4,571
4,604
3,283
5,417
2,552
3,000
2,739
3,700
4,570
5,292
6,395
6,224
7,802
5,190
3,926
4,954
4,690
5,340
4,603
6,080
6,797
5,997
5,9976,7976,0804,6035,3404,6904,9543,9265,1907,8026,2246,3955,2924,5703,7002,7393,0002,5525,4173,2834,6044,57114,6779,1448,7655,0294,5482,6024,1823,9352,1012752276997126196305671,4525301,0211,1551,7661,5791,027573455676594405551267660451385253681401307446566539600777809764073770981201,5251,7921,60509697185717295864281691085000110181
       Other Current Liabilities 
4
9
6
4
5
4
7
-38
5
12
0
131
0
0
0
0
0
0
1,372
1,605
1,792
1,525
0
1,231
1,434
1,505
0
1,865
2,009
2,231
1,418
1,324
1,296
1,422
979
1,209
595
555
750
839
790
831
588
656
606
710
877
1,034
755
816
1,347
1,571
1,505
2,308
1,500
675
652
576
152
90
484
615
817
442
2,080
1,059
1,664
2,940
1,778
2,814
1,714
1,265
1,788
714
506
1,041
985
-363
1,156
1,173
1,076
1,093
1,149
1,231
1,147
-217
0
965
1,219
1,339
2,049
2,461
2,049
2,0492,4612,0491,3391,2199650-2171,1471,2311,1491,0931,0761,1731,156-3639851,0415067141,7881,2651,7142,8141,7782,9401,6641,0592,080442817615484901525766526751,5002,3081,5051,5711,3478167551,0348777106066565888317908397505555951,2099791,4221,2961,3241,4182,2312,0091,86501,5051,4341,23101,5251,7921,6051,3720000001310125-387454694
   > Long-term Liabilities 
40
32
21
21
22
32
31
48
0
5
108
6
11
17
24
7,704
25
34
41
51
54
450
0
100
137
136
0
81
93
101
112
117
82
97
125
127
94
101
121
142
147
164
189
210
239
291
655
1,726
142
104
123
1,155
1,021
530
1,452
567
630
619
712
699
597
5,936
4,726
5,137
6,676
3,363
5,170
3,045
2,837
2,630
1,103
808
559
284
4,562
4,179
4,004
3,766
3,618
3,932
3,264
2,918
2,666
2,290
1,938
1,943
1,266
2,067
1,519
1,000
618
127
95
951276181,0001,5192,0671,2661,9431,9382,2902,6662,9183,2643,9323,6183,7664,0044,1794,5622845598081,1032,6302,8373,0455,1703,3636,6765,1374,7265,9365976997126196305671,4525301,0211,1551231041421,72665529123921018916414714212110194127125978211711210193810136137100045054514134257,7042417116108504831322221213240
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
117
82
97
125
127
94
101
121
142
147
164
189
210
239
291
655
1,726
142
104
123
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000001231041421,7266552912392101891641471421211019412712597821170000000000000000000000000000000
> Total Stockholder Equity
44
35
29
20
12
5
1
-31
63
38
200
704
432
225
-163
-7,911
-724
-1,421
-1,816
-2,491
-3,024
-2,143
0
-2,444
-1,593
-1,787
0
-2,281
-2,292
-2,568
-1,743
3
-470
-623
-459
2,666
2,247
2,336
1,488
817
253
4,459
3,982
3,481
2,355
4,535
2,739
860
10,600
8,901
6,675
19,661
17,837
15,521
14,128
12,572
11,872
10,527
9,902
8,243
7,290
5,195
5,880
3,834
12,873
9,978
5,016
326
-4,516
-6,777
-12,223
9,011
9,822
25,978
35,464
36,201
30,172
24,926
19,342
14,487
7,851
1,388
-3,015
-4,840
-3,882
-2,582
-4,858
-5,550
-3,527
-6,057
-7,764
-7,457
-6,057
-6,057-7,457-7,764-6,057-3,527-5,550-4,858-2,582-3,882-4,840-3,0151,3887,85114,48719,34224,92630,17236,20135,46425,9789,8229,011-12,223-6,777-4,5163265,0169,97812,8733,8345,8805,1957,2908,2439,90210,52711,87212,57214,12815,52117,83719,6616,6758,90110,6008602,7394,5352,3553,4813,9824,4592538171,4882,3362,2472,666-459-623-4703-1,743-2,568-2,292-2,2810-1,787-1,593-2,4440-2,143-3,024-2,491-1,816-1,421-724-7,911-1632254327042003863-31151220293544
   Common Stock
1
1
1
2
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
0
2
2
3
0
3
3
3
4
5
5
5
5
6
6
6
6
6
6
7
7
7
7
8
8
8
10
10
11
13
13
13
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
0
13
14
14
14
15
16
16151414141301212121212121212121212121212121111111111111111111111111111111111131313111010888777766666655554333032202111111111111111212111
   Retained Earnings -232,403-229,500-226,636-223,663-220,955-218,414-215,013-209,435-208,209-202,880-197,821-192,803-185,945-178,904-173,544-167,354-162,018-155,749-149,087-137,272-132,784-125,390-117,276-109,584-103,950-99,050-94,023-88,640-85,464-82,373-80,075-80,351-77,948-76,908-75,123-74,499-72,893-71,931-70,141-68,757-66,154-63,889-61,653-58,923-56,502-54,518-52,407-51,190-50,108-48,590-47,508-46,929-45,780-44,950-44,078-42,656-41,962-40,865-40,160-39,674-38,970-38,356-37,741-37,638-37,017-36,474-35,960-35,334-34,606-33,750-32,488-30,582-29,120-27,968-26,244-24,217-23,169-22,319-21,704-20,780-19,742-19,002-18,439-1,739-142-163-127-112-101-89-73-59-51
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,203
44,986
45,560
45,761
46,027
51,381
51,483
52,064
52,456
55,717
55,138
55,370
67,092
67,814
68,317
83,537
83,978
84,265
84,258
84,492
84,754
85,015
85,014
85,140
85,227
85,535
85,944
86,196
93,935
94,199
94,620
98,325
99,423
102,796
105,042
134,389
142,594
163,238
184,655
192,054
192,294
192,384
192,990
193,495
193,900
0
0
198,144
204,431
0
0
0
0
0
0
0
0
00000000204,431198,14400193,900193,495192,990192,384192,294192,054184,655163,238142,594134,389105,042102,79699,42398,32594,62094,19993,93586,19685,94485,53585,22785,14085,01485,01584,75484,49284,25884,26583,97883,53768,31767,81467,09255,37055,13855,71752,45652,06451,48351,38146,02745,76145,56044,98644,203000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
94
94
101
74
75
74
81
82
84
1,719
24,907
25,101
24,117
24,348
24,357
15,803
22,443
22,794
24,427
25,595
26,214
28,556
0
31,304
33,011
33,544
0
34,190
34,722
35,067
36,531
38,359
38,500
39,051
40,400
43,531
44,209
44,986
46,418
45,767
46,033
51,388
51,490
52,064
52,456
55,717
55,138
55,370
67,092
67,814
69,528
83,537
83,978
84,265
85,555
84,492
84,754
85,015
85,014
85,140
85,227
85,535
85,944
86,196
98,326
98,607
99,028
99,365
99,423
102,796
105,042
134,389
142,594
163,238
184,539
191,938
192,178
192,268
192,874
193,379
193,784
194,179
194,794
198,028
204,315
206,841
0
212,851
217,414
217,592
218,858
222,028
226,330
226,330222,028218,858217,592217,414212,8510206,841204,315198,028194,794194,179193,784193,379192,874192,268192,178191,938184,539163,238142,594134,389105,042102,79699,42399,36599,02898,60798,32686,19685,94485,53585,22785,14085,01485,01584,75484,49285,55584,26583,97883,53769,52867,81467,09255,37055,13855,71752,45652,06451,49051,38846,03345,76746,41844,98644,20943,53140,40039,05138,50038,35936,53135,06734,72234,190033,54433,01131,304028,55626,21425,59524,42722,79422,44315,80324,35724,34824,11725,10124,9071,7198482817475741019494



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue849
Cost of Revenue-240
Gross Profit849609
 
Operating Income (+$)
Gross Profit849
Operating Expense-11,453
Operating Income-11,693-10,604
 
Operating Expense (+$)
Research Development4,411
Selling General Administrative7,042
Selling And Marketing Expenses0
Operating Expense11,45311,453
 
Net Interest Income (+$)
Interest Income0
Interest Expense-77
Other Finance Cost-0
Net Interest Income-77
 
Pretax Income (+$)
Operating Income-11,693
Net Interest Income-77
Other Non-Operating Income Expenses0
Income Before Tax (EBT)11,623-11,763
EBIT - interestExpense = -11,623
23,246
11,700
Interest Expense77
Earnings Before Interest and Taxes (EBIT)-11,54611,700
Earnings Before Interest and Taxes (EBITDA)-11,306
 
After tax Income (+$)
Income Before Tax11,623
Tax Provision-0
Net Income From Continuing Ops-11,62311,623
Net Income11,623
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses11,693
Total Other Income/Expenses Net7077
 

Technical Analysis of Brainstorm Cell Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Brainstorm Cell Therapeutics Inc. The general trend of Brainstorm Cell Therapeutics Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Brainstorm Cell Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Brainstorm Cell Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Brainstorm Cell Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.77 < 0.8 < 1.

The bearish price targets are: 0.64 > 0.521.

Know someone who trades $BCLI? Share this with them.πŸ‘‡

Brainstorm Cell Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Brainstorm Cell Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Brainstorm Cell Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Brainstorm Cell Therapeutics Inc. The current macd is -0.00641651.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Brainstorm Cell Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Brainstorm Cell Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Brainstorm Cell Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Brainstorm Cell Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartBrainstorm Cell Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Brainstorm Cell Therapeutics Inc. The current adx is 12.94.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Brainstorm Cell Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Brainstorm Cell Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Brainstorm Cell Therapeutics Inc. The current sar is 0.765248.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Brainstorm Cell Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Brainstorm Cell Therapeutics Inc. The current rsi is 49.05. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Brainstorm Cell Therapeutics Inc Daily Relative Strength Index (RSI) ChartBrainstorm Cell Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Brainstorm Cell Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 3/(-6 +6).

  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Brainstorm Cell Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Brainstorm Cell Therapeutics Inc Daily Stochastic Oscillator ChartBrainstorm Cell Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Brainstorm Cell Therapeutics Inc. The current cci is -57.11257231.

Brainstorm Cell Therapeutics Inc Daily Commodity Channel Index (CCI) ChartBrainstorm Cell Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Brainstorm Cell Therapeutics Inc. The current cmo is 0.14207104.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Brainstorm Cell Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartBrainstorm Cell Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Brainstorm Cell Therapeutics Inc. The current willr is -50.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Brainstorm Cell Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Brainstorm Cell Therapeutics Inc Daily Williams %R ChartBrainstorm Cell Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Brainstorm Cell Therapeutics Inc. The current atr is 0.06092441.

Brainstorm Cell Therapeutics Inc Daily Average True Range (ATR) ChartBrainstorm Cell Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Brainstorm Cell Therapeutics Inc. The current obv is 51,288,878.

Brainstorm Cell Therapeutics Inc Daily On-Balance Volume (OBV) ChartBrainstorm Cell Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Brainstorm Cell Therapeutics Inc. The current mfi is 49.60.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Brainstorm Cell Therapeutics Inc Daily Money Flow Index (MFI) ChartBrainstorm Cell Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Brainstorm Cell Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-07-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-10-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-10-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Brainstorm Cell Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Brainstorm Cell Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.046
Ma 20Greater thanMa 500.699
Ma 50Greater thanMa 1000.685
Ma 100Greater thanMa 2000.872
OpenGreater thanClose0.675
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Brainstorm Cell Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Brainstorm Cell Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Brainstorm Cell Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Brainstorm Cell Therapeutics Inc

I send you an email if I find something interesting about Brainstorm Cell Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Brainstorm Cell Therapeutics Inc.

Receive notifications about Brainstorm Cell Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.